Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiko Pharmaceutical CoTSE:4574 -0.38%63 Interest Coverage is No Debt (1) as of Jun. 2026, which is 100% below its 10-year median of 284.43. GuruFocus rates TSE:4574 with a GF Score™ of 63/100 and a GF Value™ of 円264.04 (Fairly Valued). The stock has 4 warning signs investors should review. Among 684 Drug Manufacturers companies, Taiko Pharmaceutical Co ranks better than 76.17% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Taiko Pharmaceutical Co's
Operating Income
for the
three
months ended in Jun. 2026 was 円0 Mil. Taiko Pharmaceutical Co's Interest Expense for the
three
months ended in Jun. 2026 was 円0 Mil.
Taiko Pharmaceutical Co has no debt.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Taiko Pharmaceutical Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Taiko Pharmaceutical Co's Interest Coverage or its related term are showing as below:
TSE:4574'
s Interest Coverage Range Over the Past 10 Years
Min: 78.75 Med: 284.43 Max: 9707.05
Current: 79
TSE:4574's Interest Coverage is ranked better than 76.17% of 684
companies
in the Drug Manufacturers industry
Industry Median: 13.035
vs TSE:4574: 79.00
Taiko Pharmaceutical Co (TSE:4574) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Taiko Pharmaceutical Co Interest Coverage Related Terms
Taiko Pharmaceutical Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for Taiko Pharmaceutical Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Taiko Pharmaceutical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiko Pharmaceutical Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Taiko Pharmaceutical Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Taiko Pharmaceutical Co's Interest Coverage falls into.
Taiko Pharmaceutical Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Taiko Pharmaceutical Co (TSE:4574) has a Interest Coverage of No Debt (1) as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Taiko Pharmaceutical Co and its competitors. This is 100% below median its historical median of 284.43. Over the past decade, Taiko Pharmaceutical Co's Interest Coverage has ranged from 78.75 to 9,707.05. According to the industry distribution chart, Taiko Pharmaceutical Co ranks #163 out of 684 companies in the Drug Manufacturers industry, placing it in the top 23.8%.
Is Taiko Pharmaceutical Co's Interest Coverage too high?
Taiko Pharmaceutical Co's current Interest Coverage of No Debt (1) is 100% below median its 10-year median of 284.43. Over the past 10 years, this metric has ranged from a low of 78.75 to a high of 9,707.05. Based on the distribution chart, Taiko Pharmaceutical Co ranks #163 out of 684 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Taiko Pharmaceutical Co has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiko Pharmaceutical Co's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Taiko Pharmaceutical Co ranks #163 out of 684 companies for Interest Coverage. This places Taiko Pharmaceutical Co in the top 24% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 13.04. Historically, Taiko Pharmaceutical Co's own Interest Coverage has ranged from 78.75 to 9,707.05 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 13.04, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Taiko Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 13.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiko Pharmaceutical Co's current Interest Coverage is No Debt (1), which is 100% below median its own 10-year median of 284.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiko Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Taiko Pharmaceutical Co (TSE:4574) is currently considered Fairly Valued. The stock's GF Value™ is 円264.04, compared to a current price of 円263.00 — trading 0.4% below its estimated fair value. The current Interest Coverage is No Debt (1), which is 100% below median its 10-year median of 284.43. Taiko Pharmaceutical Co's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Taiko Pharmaceutical Co (TSE:4574), the current Interest Coverage is No Debt (1) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiko Pharmaceutical Co (TSE:4574) Overvalued in 2026?
Based on GuruFocus' analysis, Taiko Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円263.00 is trading 0.4% below its estimated GF Value™ of 円264.04.
GuruFocus considers Taiko Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4574:
Interest Coverage: No Debt (1) (100% below median its 10-year median of 284.43)
GF Value™: 円264.04 vs. price of 円263.00 (0.4% below fair value)
No single metric tells the full story. See the TSE:4574 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.
63GF Score
Get the complete analysis for TSE:4574
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4574 has been successfully added to your 
